Natural history of alkaptonuria

New England Journal of Medicine

Volumn 347, Issue 26, 2002, Pages 2111-2121

  Phornphutkul, Chanika ^a   Introne, Wendy J ^a   Perry, Monique B ^b   Bernardini, Isa ^a   Murphey, Mark D ^c,d,e   Fitzpatrick, Diana L ^a   Anderson, Paul D ^a   Huizing, Marjan ^a   Anikster, Yair ^a   Gerber, Lynn H ^b   Gahl, William A ^a,f  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOGENTISIC ACID; NITISINONE; TYROSINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALKAPTONURIA; ARTERY CALCIFICATION; ARTICLE; CHILD; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY; DISEASE SEVERITY; ENZYME DEFICIENCY; FEMALE; GENE MUTATION; HUMAN; JOINT PROSTHESIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NUCLEOTIDE SEQUENCE; OCHRONOSIS; PRIORITY JOURNAL;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALKAPTONURIA; CHILD; CHILD, PRESCHOOL; CONNECTIVE TISSUE DISEASES; CYCLOHEXANONES; DIOXYGENASES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; ENZYME INHIBITORS; FEMALE; HEART VALVE DISEASES; HOMOGENTISATE 1,2-DIOXYGENASE; HUMANS; JOINT DISEASES; KIDNEY CALCULI; LIFE TABLES; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; NITROBENZOATES; OXYGENASES; SEVERITY OF ILLNESS INDEX; TYROSINE;

EID: 0037180818     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021736     Document Type: Article

References (38)

1. Garrod E. The incidence of alkaptonuria: A study in chemical individuality. Lancet 1902;2:1616-20.
2. Idem. The Croonian lectures on inborn errors of metabolism. Lecture II. Alkaptonuria. Lancet 1908;2:73-9.
3. La Du BN. Alkaptonuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th Ed. Vol. 2. New York: McGraw-Hill, 2001:2109-23.
4. La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alkaptonuria. J Biol Chem 1958;230:251-60.
5. Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D, et al. The molecular basis of alkaptonuria. Nat Genet 1996;14:19-24.
6. La Du BN. Alkaptonuria. In: Royce PM, Steinmann B, eds. Connective Tissue and Its Heritable Disorders. 2nd Ed. New York: John Wiley, 2002:809-26.
7. O'Brien WM, La Du BN, Bunim JJ. Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: Review of world literature (1584-1962). Am J Med 1963;34:813-38.
8. Wolff JA, Barshop B, Nyhan WL, et al. Effects of ascorbic acid in alkaptonuria: Alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res 1989;26:140-4.
9. Anikster Y, Nyhan WL, Gahl WA. NTBC and alkaptonuria. Am J Hum Genet 1998;63:920-1.
10. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340:813-7.
11. Ware JE Jr, Brook RH, Davies AR, Lohr KN. Choosing measures of health status for individuals in general populations. Am J Public Health 1981;71:620-5.
12. Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
13. Schober P. Lendenwirbelsäule und kreuzschmerzen. Munch Med Wochenschr 1937;84:336-8.
14. Macrae IF, Wright V. Measurement of back movement. Ann Rheum Dis 1969;28:584-9.
15. Lustberg TJ, Schulman JD, Seegmiller JE. The preparation and identification of various adducts of oxidized homogentisic acid and the development of a new sensitive colorimetric assay for homogentisic acid. Clin Chim Acta 1971;35:325-33.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd Ed. Plainview, N.Y.: Cold Spring Harbor Laboratory Press, 1989.
17. Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab 2002;77:136-42.
18. Motulsky H. Intuitive biostatistics. New York: Oxford University Press, 1995:55-7.
19. Bahn AK. Basic Medical Statistics. New York: Grune & Stratton, 1972:154-5.
20. Moll JMH, Wright V. Normal range of spinal mobility: An objective clinical study. Ann Rheum Dis 1971;30:381-6.
21. Deutsch JC, Santhosh-Kumar CR. Quantitation ofhomogentisic acid in normal human plasma. J Chromatogr B Biomed Appl 1996;677:147-51.
22. Beltran-Valero de Bernabe D, Granadino B, Chiarelli I, et al. Mutation and polymorphism analysis of the human homogentisate 1,2-dioxygenase gene in alkaptonuria patients. Am J Hum Genet 1998;62:776-84.
23. Stenn FF, Milgram JW, Lee SL, Weigand RJ, Veis A. Biochemical identification of homogentisic acid pigment in an ochronotic Egyptian mummy. Science 1977;197:566-8.
24. Boedeker C. Ueber das Alcapton: Ein neuer beitrag zur frage: Welche stoffe des hams können kupferreduction bewirken? Z Ration Med 1859; 7:130-45.
25. Wolkow M, Baumann E. Ueber das wesen der alkaptonurie. Z Physiol Chem 1891;15:228-85.
26. Neubauer O. Über den abbau der aminosäiuren im gesunden und kranken organismus. Dtsch Arch Klin Med 1909;95:211-56.
27. Khan MA. Ankylosing spondylitis. In: Calin A, ed. Spondylarthropathies. Orlando, Fla.: Grune & Stratton, 1984:69-117.
28. Beltran-Valero de Bernabe D, Jimenez FJ, Aquaron R, Rodriguez de Cordoba S. Analysis of alkaptonuria (AKU) mutations and polymorphisms reveals that the CCC sequence motif is a mutational hot spot in the homogentisate 1,2 dioxygenase gene (HGO). Am J Hum Genet 1999;64:1316-22.
29. Zatkova A, de Bernabe DB, Polakova H, et al. High frequency of alkaptonuria in Slovakia: Evidence for the appearance of multiple mutations in HGO involving different mutational hot spots. Am J Hum Genet 2000; 67:1333-9. [Erratum, Am J Hum Genet 2000;68:1313.]
30. Rodriguez JM, Timm DE, Titus GP, et al. Structural and functional analysis of mutations in alkaptonuria. Hum Mol Genet 2000;9:2341-50.
31. Porfirio B, Chiarelli I, Graziano C, et al. Alkaptonuria in Italy: Polymorphic haplotype background, mutational profile, and description of four novel mutations in the homogentisate 1,2-dioxygenase gene. J Med Genet 2000;37:309-12.
32. Srsen S, Muller CR, Fregin A, Srsnova K. Alkaptonuria in Slovakia: Thirty-two years of research on phenotype and genotype. Mol Genet Metab 2002;75:353-9.
33. de Jorge EG, Lorda I, Gallardo ME, et al. Alkaptonuria in the Dominican Republic: Identification of the founder AKU mutation and further evidence of mutation hot spots in the HGO gene. J Med Genet 2002;39:Suppl:E40. abstract.
34. Schulz A, Ort O, Beyer P, Kleinig H. SC-0051, a 2-benzoyl-cyclohexane-1,3-dione bleaching herbicide, is a potent inhibitor of the enzyme p-hydroxyphenylpyruvate dioxygenase. FEBS Lett 1993;318:162-6.
35. Ellis MK, Whitfield AC, Gowans LA, et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Toxicol Appl Pharmacol 1995;133:12-9.
36. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th Ed. Vol. 2. New York: McGraw-Hill, 2001:1777-805.
37. Hall MG, Wilks MF, Provan WM, Eksborg S, Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromerhylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol 2001;52:169-77.
38. Suzuki Y, Oda K, Yoshikawa Y, Maeda T, Suzuki T. A novel therapeutic trial ofhomogentisic aciduria in a murine model of alkaptonuria. J Hum Genet 1999;44:79-84.